University of Southern California
Raymond Stevens is the founding director of the iHuman Institute at ShanghaiTech University in Shanghai, China and the Provost Professor of Chemistry and Molecular Biology, founding director of the Bridge Institute at the University of Southern California (USC). He holds joint appointments in the Viterbi School of Engineering and Keck School of Medicine. His research has helped to advance the area of high throughput structural biology — essential work for understanding the human body at atomic resolution as well as critical for pharmaceutical drug development. He has helped develop several therapeutic molecules that have become breakthrough drugs to treat conditions ranging from rare childhood diseases to neuromuscular disorders and diabetes (associated with 4 marketed drugs and 2 in clinical trials). He has authored more than 350 peer-reviewed publications in the area of human cell signaling. His laboratory has launched four biotech startups (Syrrx, acquired by Takeda; MemRx, acquired by Novartis; Receptos, which had an initial public offering (RCPT) in May 2013 acquired by Celgene in 2015; and RuiYi, located in Shanghai, China), and 3 NIH Centers. Stevens earned his undergraduate degree in chemistry from the University of Southern Maine and his Ph.D. in chemistry from USC where he worked with Professors Robert Bau and George Olah. Stevens then conducted postdoctoral research in structural biology in the chemistry department at Harvard University with Professor William Lipscomb. Thomson Reuters named Stevens as having one of “The World’s Most Influential Scientific Minds” for 2014 and 2015. His research accolades include the National Science Foundation’s Presidential Young Investigator Award, Beckman Foundation’s Young Investigator Award, Lawrence Berkeley Laboratory Outstanding Performance Award, Jouan Robotics Award, Sidhu Award, the Qian Ren Award, and the Zhao Chenggu SIMM Award for International Drug Discovery.